Mirogabalin: legal
This page summarises mirogabalin's status in the places checked; it is not legal advice, and it does not cover every country or state.
Japan
On 8 January 2019 Daiichi Sankyo “announced the receipt of marketing approval in Japan” for Tarlige tablets, “generic name: mirogabalin besylate”, “for the treatment of peripheral neuropathic pain”.[1] It is a prescription medicine there.
United States
Mirogabalin is not an approved medicine in the United States, and it does not appear by name anywhere in the federal “Schedules of Controlled Substances”, read in full on 2026-11-19.[2] Its better-known relative pregabalin is in federal Schedule V, listed as “Pregabalin [(S)-3-(aminomethyl)-5-methylhexanoic acid] 2782”.[2] Mirogabalin acts at the same calcium-channel site but is a different compound, so that listing does not cover it. Not being federally scheduled is not the same as being legal to sell for consumption, and state law was not checked for this page.
Sport
The World Anti-Doping Agency's list, which states “This List shall come into effect on 1 January 2026.”, does not name mirogabalin.[3]
References
- Daiichi Sankyo Announces Marketing Approval in Japan of 'Tarlige Tablets' for Pain Treatment (press release, 8 January 2019) — Daiichi Sankyo Company, Limited
- 21 CFR part 1308, Schedules of Controlled Substances, full text as of 2026-11-13 (eCFR versioner, read 2026-11-19) — US Drug Enforcement Administration, via eCFR (National Archives)
- World Anti-Doping Code International Standard: Prohibited List 2026, Wayback capture of 19 November 2026 — World Anti-Doping Agency
Comments
Sign in to join the conversation.
No comments yet.